You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

KRAS G12C

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non Small Cell Lung Cancer Metastatic, Brain Metastases, Adult, KRAS G12C Trial (JDQ443)

Not yet recruiting
  • Non Small Cell Lung Cancer Metastatic
  • +2 more
  • (no location specified)
Aug 11, 2023

Advanced or Metastatic Solid Tumor, KRAS G12C Mutation Trial in Changsha (BEBT-607Tablets)

Recruiting
  • Advanced or Metastatic Solid Tumor
  • KRAS G12C Mutation
  • Changsha, Hunan, China
    Xiangya Hospital of Central South University
Nov 2, 2023

Advanced Solid Tumor, NSCLCs Trial in Houston (Adagrasib, Olaparib)

Not yet recruiting
  • Advanced Solid Tumor
  • Non-small Cell Lung Cancers
  • Houston, Texas
    M D Anderson Cancer Center
Nov 15, 2023

Efficacy Trial in Seoul (Oral sotorasib + IV Panitumumab)

Active, not recruiting
  • Efficacy
  • Oral sotorasib + IV Panitumumab
  • Seoul, Korea, Republic of
    Korea University Anam Hospital
Aug 14, 2023

Advanced NSCLC With KRAS G12C Mutation Trial in New York (Sotorasib, Ladarixin)

Not yet recruiting
  • Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
  • New York, New York
    NYU Langone Health
Apr 4, 2023

Advanced NSCLC With KRAS G12C Mutation Trial in New York (Sotorasib, Ladarixin)

Not yet recruiting
  • Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
  • New York, New York
    NYU Langone Health
Apr 4, 2023

Advanced Cancer, Metastatic Cancer, Malignant Tumor of Lung Trial in Santa Rosa (Adagrasib)

Recruiting
  • Advanced Cancer
  • +2 more
  • Santa Rosa, California
    Providence Medical Foundation
May 2, 2023

Advance NSCLC Trial (GFH925, Cetuximab)

Not yet recruiting
  • Advance Non-small Cell Lung Cancer
  • (no location specified)
Mar 7, 2023

KRAS G12C Trial in Guangzhou (GFH925)

Recruiting
  • KRAS G12C
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's Hospital
Aug 1, 2022

Lung Cancer, Gastro-intestinal Cancer Trial in Houston (Durvalumab, Adagrasib)

Not yet recruiting
  • Lung Cancer
  • Gastro-intestinal Cancer
  • Houston, Texas
    M D Anderson Cancer Center
May 9, 2023

Solid Tumor, Adult, NSCLC, Advanced Cancer Trial (Adagrasib, nab-Sirolimus)

Not yet recruiting
  • Solid Tumor, Adult
  • +4 more
  • (no location specified)
Apr 24, 2023

Metastatic Pancreatic Cancer Trial in Houston (MRTX849)

Not yet recruiting
  • Metastatic Pancreatic Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Nov 22, 2022

NSCLC (NSCLC) Colorectal Cancer (CRC) Pancreatic Ductal Adenocarcinoma Advanced Solid Tumors Trial in Irving, San Antonio,

Not yet recruiting
  • Non-Small Cell Lung Cancer (NSCLC) Colorectal Cancer (CRC) Pancreatic Ductal Adenocarcinoma Advanced Solid Tumors
  • Assigned interventions
  • Irving, Texas
  • +2 more
Nov 7, 2023

Solid Tumor, Adult, Metastatic Solid Tumor, Metastatic NSCLC Trial in Adelaide (BBP-398, sotorasib)

Recruiting
  • Solid Tumor, Adult
  • +3 more
  • Adelaide, South Australia, Australia
    Cancer Research SA
Aug 15, 2022

Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer Trial in United States (VS-6766 and adagrasib)

Recruiting
  • Non Small Cell Lung Cancer
  • +5 more
  • avutometinib (VS-6766) and adagrasib
  • San Francisco, California
  • +4 more
Dec 21, 2022

RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC

Recruiting
  • Nsclc
  • KRAS P.G12C
    • Paris, France
    • +2 more
    Aug 9, 2022

    Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, NSCLC Trial (ELI-002 7P)

    Not yet recruiting
    • Pancreatic Ductal Adenocarcinoma
    • +14 more
    • ELI-002 7P
    • (no location specified)
    Feb 3, 2023

    KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, NSCLC Trial (JDQ443, trametinib, Ribociclib)

    Recruiting
    • KRAS G12C Mutant Solid Tumors
    • +10 more
    • Boston, Massachusetts
    • +5 more
    Jan 11, 2023

    Advanced NSCLC, Metastatic Lung Cancer Trial in East Syracuse, Cleveland, Bellingham (Adagrasib in combination with

    Recruiting
    • Advanced NSCLC
    • Metastatic Lung Cancer
    • Adagrasib in combination with pembrolizumab
    • Pembrolizumab
    • East Syracuse, New York
    • +2 more
    Nov 28, 2022

    Resectable NSCLC Trial (Adagrasib, Adagrasib/Nivolumab)

    Not yet recruiting
    • Resectable Non-Small Cell Lung Cancer
    • (no location specified)
    Jul 21, 2022

    Colorectal Cancer Trial in Hangzhou (IBI351)

    Not yet recruiting
    • Colorectal Cancer
    • Hangzhou, Zhejiang, China
      The Second Affiliated Hospital of Zhejiang University School of
    Aug 9, 2022

    NSCLC Trial in Philadelphia (Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days))

    Recruiting
    • Non-Small Cell Lung Cancer
    • Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
    • Philadelphia, Pennsylvania
      Fox Chase Cancer Center
    Jul 29, 2022

    NSCLC Trial in Busan (GDC-6036, Pembrolizumab)

    Recruiting
    • Non-Small Cell Lung Cancer
    • Busan, Korea, Republic of
      Pusan National University Hospital
    Apr 3, 2023

    Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer Trial in Santa Monica, Plantation (HBI-2438)

    Not yet recruiting
    • Lung Cancer
    • +6 more
    • Santa Monica, California
    • +1 more
    Aug 2, 2022

    NSCLC Trial in United States (VIC-1911, sotorasib)

    Recruiting
    • Non-small Cell Lung Cancer
    • Sacramento, California
    • +4 more
    Jan 5, 2023